Sensus Healthcare (SRTS) Earnings Date & Reports

Key Takeaways

• Sensus Healthcare is expected to report third-quarter 2026 results after the market closes on November 12, 2026, with a conference call to follow.
• Consensus estimates point to a loss of roughly $0.06 per share on revenue near $6.61 million, compared with a loss of $0.06 per share and revenue of $6.88 million in the year-ago quarter.
• The quarter is the second full period under new dedicated CPT (Current Procedural Terminology) reimbursement codes that took effect January 1, 2026, a change management sees as a key adoption driver for its superficial radiotherapy (SRT) systems.
• Investors will watch whether eight device sales delayed out of the second quarter by financing timing, and expected to be recognized in the third quarter, show up in reported revenue.
• Prior results have missed consensus in recent quarters, making revenue recognition, unit shipments, and gross margin the central questions heading into the report.
• For more information on the ticker's Major News, Today's Price Move, Price Targets, and Forecast, readers can explore the dedicated pages for additional context and data.
• Explore Trending AI Robots to see how AI-driven trading tools are scanning the market for emerging opportunities.

Earnings Context and Why It Matters

Sensus Healthcare's third-quarter report is a pivotal checkpoint in its effort to move from a concentrated, lumpy sales model toward broader, more diversified adoption of its SRT-100 and SRT-100 Vision devices. The company spent the first half of 2026 educating physicians on new dedicated CPT reimbursement codes, which management says have improved customer economics and shortened adoption timelines. Yet the financial transition has been uneven: second-quarter revenue of $2.29 million fell sharply year over year, partly because eight units slipped into the third quarter on financing-approval delays. With management guiding toward a stronger second half, this report will test whether the reimbursement-driven pipeline is converting into recognizable revenue and whether the company can rebuild momentum toward its stated goal of full-year profitability.

Earnings Expectations

Heading into the report, consensus estimates call for a third-quarter loss of approximately $0.06 per share on revenue of about $6.61 million. The year-ago quarter delivered a loss of $0.06 per share on revenue of $6.88 million, meaning analysts expect revenue to decline modestly year over year while losses hold roughly flat. The bar is set low relative to the company's historical results, but recent quarters have consistently missed consensus on both lines.

In the second quarter, Sensus reported revenue of $2.29 million and a net loss of $8.7 million, or $0.53 per share, well below expectations. Management attributed the shortfall to financing-approval timing that pushed eight unit sales into the third quarter, and it has said those units were subsequently approved and sold at an average price near $250,000. Investors will therefore focus less on the headline estimate and more on unit shipments, the split between outright purchases and recurring revenue arrangements, gross margin, and any commentary on the strength of the second-half pipeline.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is built to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, helping investors narrow a broad universe to a focused watchlist. For those monitoring names like Sensus Healthcare alongside its medical-device peers, the AI Screener offers a practical way to compare signals and momentum across the sector.

Market Reaction and Investor Sentiment

Sentiment into Sensus Healthcare's third-quarter report is cautious but attentive. The stock has faced pressure as consecutive quarters missed consensus and revenue contracted sharply from prior-year levels, largely reflecting the transition away from a historically dominant customer. At the same time, bulls point to the new reimbursement codes, a growing pipeline, the shift toward recurring revenue through the Fair Deal Agreement program and Sensus Link software, and management's explicit expectation that the second half will be stronger than the first. The market's reaction will likely hinge on whether the delayed second-quarter sales actually appear in third-quarter revenue and whether gross margin stabilizes after declining to 29.2% in the first quarter. A revenue miss or a further margin slide could renew concerns about the pace of the recovery.

Forward Outlook and Key Factors to Monitor

Looking beyond the third-quarter print, investors should watch several interconnected factors that will shape Sensus Healthcare's trajectory. The first is revenue conversion. Management has indicated that eight units delayed from the second quarter should be recognized in the third, and commentary on fourth-quarter shipment expectations will signal whether that recovery is durable or simply a timing shift.

Second is the reimbursement landscape. The dedicated CPT codes became effective at the start of 2026, and the company has highlighted a proposed 26% increase in a hospital-based delivery code. Any update on physician adoption, billing patterns, or payer dynamics will matter for the demand outlook.

Third is recurring revenue. Growth in the Fair Deal Agreement program, rental placements, and Sensus Link software adoption is central to management's goal of reducing revenue lumpiness and building a more predictable base. Fourth, margins and expenses deserve attention. Product mix, including a higher proportion of international shipments and placement costs, has pressured gross margin, so any improvement here would support the path toward profitability. Finally, the company's cash position of roughly $15.2 million with no debt at the end of the second quarter provides a runway, but investors will monitor cash burn as the commercial buildout continues.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations